Septerna, Inc. (SEPN) stock intrinsic value fair value estimate & owner earnings analysis

Septerna is a clinical-stage biotechnology company built around a platform for finding oral, pill-type drugs that act on GPCRs, a large family of receptors on the surface of cells. It has no products for sale. Its revenue is research revenue from a single active partner, Novo Nordisk. In May 2025 Novo agreed to a global collaboration on oral small-molecule drugs for metabolic disease (targets include the GLP-1, GIP and glucagon receptors). Novo paid $195.0 million upfront in July 2025, reimburses 100% of Septerna's research costs on four joint programs, and could pay up to about $498 million of milestones per program plus mid-to-high single-digit royalties if drugs succeed. A smaller research contract with Vertex ended in September 2025, and a final $12.5 million milestone from Vertex (tied to an asset Septerna sold in 2023) was received in August 2025 with nothing further due. Septerna's own pipeline includes SEP-631 (early clinical data for a mast-cell condition) and a next-generation parathyroid-hormone-receptor drug, SEP-479; its former lead drug SEP-786 was stopped in February 2025 after two severe liver-related lab events in a Phase 1 trial. What the business earns. Reported 2025 operating cash flow of +$110 million overstates the underlying picture: it is almost entirely Novo's upfront payment arriving. Removing that timing effect and charging stock compensation as a real cost, owner earnings were about -$61.6 million in 2025 (-$1.39 per share), -$73.0 million in 2024 and -$44.1 million in 2023 (2023 and 2024 shown on the current post-IPO share count). Those figures still include $26.8 million of revenue released from the upfront and about $16 million of interest earned on the cash pile. Since the cash itself is counted separately below, we strip both out to see what the operation costs on its own. On that basis the cash burn was about $80 million in 2024 and $105 million in 2025. In the first half of 2026 operating expenses were $83.4 million against revenue of $53.3 million, of which $27.8 million was the non-cash release of the upfront; that annualizes to a net burn of about $116 million a year, or $2.6 per share, including roughly $22 million a year of stock compensation. Operating expenses rose about 51% versus the first half of 2025 and rose again from the first to the second quarter of 2026. Because the earnings are negative, there is no positive earnings level to anchor on: we anchored on the current run-rate rather than on any single year, since two consecutive quarters (about $40 million and $44 million of expense) confirm the higher level. For year one we assume a burn 11% above 2025, less than the roughly 30% increase in burn seen from 2024 to 2025, so no reversal of a trend is being assumed. Balance sheet. At June 30, 2026 Septerna held $516.5 million of cash and marketable securities ($11.47 per share) against 45.0 million shares, and has no borrowings. Its $22.5 million of lease obligations and $140.4 million of deferred revenue are not treated as debt: the deferred revenue is a service obligation whose cash has already been received and is already counted in the cash figure, and the costs of doing that work run through the burn above. Management says the cash funds operations at least into 2029, consistent with our estimate. Our three cases. Each is valued as the cash on hand minus the present value (at 6%) of the burn the business will consume, and each stops when the cash runs out. We give no credit for milestones, royalties or the success of any drug candidate, because none of that is secured: Novo's milestones depend on clinical and regulatory success by Novo, the Vertex payments are finished, and the company's own drugs have no revenue and one lead candidate has already failed. - Bear ($1.45 per share): burn keeps rising about 10% a year for three years, following the recent cost trend, and Novo's reimbursements end when the four programs reach candidate selection, leaving overhead behind. Cash runs out around mid-2030. The ongoing operation absorbs about $451 million of present value against $516.5 million of cash; there is no debt, so about $65 million, or $1.45 per share, is left. Named risks include the February 2025 failure of SEP-786 (after which spending still rose) and dependence on China-based manufacturing partners such as WuXi STA, exposed to tariffs and the proposed BIOSECURE Act. - Base ($1.64 per share): burn stays at the current $116 million a year until the cash is exhausted in late 2030, consistent with management's own runway. The operation absorbs about $443 million of present value; about $74 million, or $1.64 per share, remains. - Bull ($1.92 per share): burn is held at the 2025 level ($105 million) for two years while the Novo programs run, then falls to the roughly $80 million a year the company actually spent in 2024. The operation absorbs about $430 million; about $86 million, or $1.92 per share, remains. What that means. On these cases the shares are worth far less than the cash they hold, because the company is spending its cash on research whose payoff we cannot credit from evidence in hand. The three cases are close together because none of them credits a payoff; the real uncertainty is whether the research succeeds, which this analysis deliberately does not price. The result is sensitive to one assumption: that the board keeps funding its own programs until the cash is gone. The 2025 record supports that view (spending rose after the SEP-786 setback), but if management cut spending sharply, value would move toward the $11.47 per share of cash. It would also be wrong if Novo's programs deliver milestone payments, if SEP-631 or SEP-479 lead to a new partnership paying cash upfront, or if the platform produces approved drugs and royalties; any of those would be upside not counted here. We could not reconcile the size or timing of Novo's near-term milestones from the filings, since only the per-program maximum is disclosed. The company also conducts some research and manufacturing work outside the United States, including in China.